SCHEMBL19966690

SCHEMBL19966690

CCNc1ccc2nsnc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 4/20 0.60
PTPN1 P18031 2/20 0.60
KDM4E B2RXH2 8/20 0.54
MAPT P10636 10/20 0.49
MEN1 O00255 8/20 0.49
KMT2A Q03164 8/20 0.49
ALDH1A1 P00352 8/20 0.49
BLM P54132 6/20 0.49
SMN1; SMN2 Q16637 6/20 0.49
NSD2 O96028 5/20 0.49
LMNA P02545 4/20 0.49
POLB P06746 2/20 0.49
HPGD P15428 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
HTT P42858 2/20 0.49
GAA P10253 4/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
APAF1 O14727 2/20 0.46
TDP2 O95551 2/20 0.46
CASP3 P42574 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13945662 0.78 KDM4E (0.59) PTPN11PTPN1KDM4EMAPTMEN1
SCHEMBL16368599 0.77 KDM4E (0.54) PTPN11PTPN1KDM4EMAPTMEN1
SCHEMBL14035880 0.74 KDM4E (0.50) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL23055245 0.73 KDM4E (0.59) PTPN11PTPN1KDM4EMAPTMEN1
SCHEMBL19966687 0.73 KDM4E (0.46) PTPN11PTPN1KDM4EMAPTMEN1
SCHEMBL17423369 0.72 MAPT (0.52) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL257319 0.69 PTPN11 (0.48) PTPN11PTPN1KDM4EMAPTMEN1
Dimethylamine SCHEMBL5392761 0.69 MAPT (0.49) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL14035669 0.69 TRPM5 (0.57) MEN1KMT2AALDH1A1SMN1; SMN2NPSR1
SCHEMBL12256522 0.69 NPC1 (0.50) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 US disclosed
US-10227340-B2 Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-03-12 US disclosed
US-20180072712-A1 THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072712-A1 THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS IRAK4, IRAK1, IRAK3 PTPN11 86/4885PTPN1 68/4885KDM4E 307/4885
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 PTPN11 3357/4885PTPN1 3775/4885KDM4E 3621/4885
US-10227340-B2 Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors IRAK4, IRAK1, IRAK3 PTPN11 86/4885PTPN1 68/4885KDM4E 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.